Top

Gepubliceerd in:

2014 | OriginalPaper | Hoofdstuk

13. Longcarcinoom

Auteur : Egbert Smit

Gepubliceerd in: Ontwikkelingen in de oncologie

Uitgeverij: Bohn Stafleu van Loghum

Inleiding

Longkanker bezet na borstkanker en darmkanker de derde plaats op de incidentieladder van maligniteiten. De incidentie in Nederland ligt rond de tienduizend nieuw gediagnosticeerde patiënten per jaar, waarbij het meestal gaat om de ‘niet-kleincellige’ vorm. Bij mannen neemt de incidentie af doordat zij sinds de jaren tachtig minder zijn gaan roken, maar bij vrouwen stijgt deze nog steeds. Een huisarts in een normpraktijk ziet één of twee nieuwe longkankerpatiënten per jaar.

vorige hoofdstuk Prostaatcarcinoom

volgende hoofdstuk Hoofd-halscarcinoom

Integraal Kankercentrum Nederland [internet]. Utrecht: VIKC, 2011. www.ikcnet.nl, geraadpleegd 30 maart 2011.

Centraal Bureau voor de Statyistiek [internet]. Den Haag: CBS, 2011. www.cbs.nl, geraadpleegd 30 maart 2011.

Greenman C, Stephens P, Smith R, Dalgliesh GL, Hunter C, Bignell G, et al. Patterns of somatic mutation in human cancer genomes. Nature 2007;446:153–8.PubMedCentralPubMedCrossRef

Thomas RK, Baker AC, Debiasi RM, Winckler W, Laframboise T, Lin WM, et al. High-throughput oncogene mutation profiling in human cancer. Nature Gen 2007;39:347–51.CrossRef

Sun S, Schiller J, Gazdar AF. Lung cancer in never smokers: A different disease. Nat Rev Cancer 2007;7:738–90.

Gazdar AF. Should we continue to use the term non-small cell lung cancer? Ann Oncol 2010;21 Suppl 7:vii225–9.

Rosell R, Moran T, Queralt C, Porta R, Cardenal F, Camps C, et al. Screening for epidermal growth factor receptor mutations in lung cancer. N Eng J Med 2009;361:958–67.CrossRef

Annema JT, Belderbos JSA, Bluemink-Holkenborg TTM, Dingemans AMC, Eerenberg JP, Van Gameren MM, et al. Niet-kleincellig longcarcinoom: Landelijke richtlijn, versie 2.0. Utrecht: Integraal Kankercentrum Nederland (IKNL), 2011.www.oncoline.nl/niet-kleincellig-longcarcinoom, geraadpleegd juni 2013.

NSCLC Meta-analyses Collaborative Group. Chemotherapy in addition to supportive care improves survival in advanced non-small-cell lung cancer: a systematic review and meta-analysis of individual patient data from 16 randomised controlled trials. J Clin Oncol 2008;26:4617–25.PubMedCentralCrossRef

10.

Von Hoff DD. David A. Karnofsky Memorial Award lecture. ASCO Annual Meeting, 2010 June 4-8, Chicago. Chicago IL: ASCO, 2010.

11.

Becker A, Van Wijk A, Smit EF, Postmus PE. Side-effects of long-term administration of erlotinib in patients with non-small cell lung cancer. J Thorac Oncol 2010;5:1477–80.PubMedCrossRef

12.

Kris MG, Natale RB, Herbst RS, Lynch TJ Jr, Prager D, Belani CP, et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: A randomized trial. JAMA 2003;290:2149–58.PubMedCrossRef

13.

Fukuoka M, Yano S, Giaccone G, Tamura T, Nakagawa K, Douillard JY, et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected]. J Clin Oncol 2003;21:2237–46.PubMedCrossRef

14.

Langer CJ. The ’lazarus response’ in treatment-naive, poor performance status patients with non-small-cell lung cancer and epidermal growth factor receptor mutation. J Clin Oncol 2009;27:1350–4.CrossRef

15.

Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004;350:2129–39.PubMedCrossRef

16.

Paez JG, Jänne PA, Lee JC, Tracy S, Greulich H, Gabriel S, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004;304:1497–500.PubMedCrossRef

17.

Pao W, Miller V, Zakowski M, Doherty J, Politi K, Sarkaria I, et al. EGF receptor gene mutations are common in lung cancers from ’never smokers’ and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA 2004;101:13306–11.PubMedCentralPubMedCrossRef

18.

Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009;361:947–57.PubMedCrossRef

19.

Maemondo M, Inoue A, Kobayashi K, Sugawara S, Oizumi S, Isobe H, et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 2010;362:2380–8.PubMedCrossRef

20.

Zhou C, Wu Y, Chen G, Feng J, Liu X, Wang C, et al. Preliminary results of randomized phase III study comparing efficacy and safety of first-line erlotinib versus carboplatin (CBDCA) plus gemcitabine (GEM) in Chinese advanced non-small cell lung cancer (NSCLC) patients (pts) with EGFR-activating mutations (OPTIMAL). General poster session, lung cancer-metastatic, 2010 ASCO Annual Meeting. J Clin Oncol 2010:28(suppl; abstr 7575).

21.

Kim ES, Hirsh V, Mok T, Socinski MA, Gervais R, Wu YL, et al. Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial. Lancet 2008;372:1809–18.PubMedCrossRef

22.

Kobayashi S, Boggon TJ, Dayaram T, Jänne PA, Kocher O, Meyerson M, et al. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med 2005;352:786–92.PubMedCrossRef

23.

Shepherd FA, Rodrigues Pereira J, Ciuleanu T, Tan EH, Hirsh V, Thongprasert S, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005;353:123–32.PubMedCrossRef

24.

Miller VA, Hirsh V, Cadranel J, et al. Phase IIB/III double-blind randomized trial of Afatinib (BIBW2992, irreversible inhibitor of EGFR/HER1 and HER2) + Best supportive care versus placebo and BSC in patients failing 1-2 lines of chemotherapy and Erlotinib or Gefitinib (LUX-Lung 1). Oral presentation, ESMO Annual Meeting, 2010 October 8-12, Milan.

25.

Engelman JA, Zejnullahu K, Mitsudomi T, Song Y, Hyland C, Park JO, et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 2007;316:1039–43.PubMedCrossRef

26.

Soda M, Choi YL, Enomoto M, Takada S, Yamashita Y, Ishikawa S, et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 2007;448:561–6.PubMedCrossRef

27.

Kwak EL, Bang YJ, Camidge DR, Shaw AT, Solomon B, Maki RG, et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 2010;363:1693–703.PubMedCentralPubMedCrossRef

28.

Shaw AT, Kim DW, Nakagawa K, Seto T, Crinò L, Ahn M-J, et al. Phase III study of crizotinib versus pemetrexed or docetaxel chemotherapy in patients with advanced ALK-positive non-small cell lung cancer (NSCLC), PROFILE 1007 [abstract]. ESMO congress, Vienna, September 28-October 2, 2012. Abstract No. 2862.

29.

Shaw AT, Yeap BY, Mino-Kenudson M, Digumarthy SR, Costa DB, Heist RS, et al. Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. J Clin Oncol 2009;27:4247–53.PubMedCentralPubMedCrossRef

Titel: Longcarcinoom
Auteur: Egbert Smit
Uitgeverij: Bohn Stafleu van Loghum
Boek: Ontwikkelingen in de oncologie
Print ISBN: 978-90-368-0435-6

Elektronisch ISBN: 978-90-368-0436-3

Copyright: 2014
DOI: https://doi.org/10.1007/978-90-368-0436-3_13

Bohn Stafleu van Loghum

Deel dit onderdeel of sectie (kopieer de link)

Inleiding

Log in om toegang te krijgen